Physician profile
Kristy B Darnell
NPI 1316244528
$39,897.15
in general payments reported to CMS, 2019-2025
60 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 83% of Neuroscience (Registered Nurse) providers received nationally (typical 2025 total: $185).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $12K · 2023: $3,162 · 2024: $6,028 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $1,700 · Travel and Lodging: $368 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,754.32 |
| Honoraria | $1,700.00 |
| Travel and Lodging | $367.80 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $11,998.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $9,282.92 | 2022 | |
| Radius Health, INC. | $2,587.40 | 2023-2024 | Tymlos |
| Biogen, INC. | $1,815.16 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $1,437.99 | 2021-2025 | |
| Amgen INC. | $971.96 | 2021-2025 | Evenity, Prolia, Prolia |
| Celgene Corporation | $832.73 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $753.33 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $739.03 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $731.70 | 2021-2025 | Ultomiris, Strensiq, Soliris |
| Lilly USA, LLC | $652.10 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $493.61 | 2021-2025 | Ingrezza |
| Eisai INC. | $479.68 | 2021-2025 | |
| Inspire Medical Systems, INC. | $469.92 | 2023-2025 | Inspire |
| Emd Serono, INC. | $447.03 | 2021-2025 | Mavenclad |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $437.34 | 2021-2025 | Xcopri |
| Pfizer INC. | $382.57 | 2023-2025 | |
| Banner Life Sciences, LLC | $380.96 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $379.29 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $344.65 | 2022-2023 | Ponvory |
| Tg Therapeutics, INC. | $340.57 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $321.34 | 2021-2024 | |
| Neurelis, INC. | $317.12 | 2021-2025 | Valtoco |
| Acorda Therapeutics, INC | $283.03 | 2021-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $270.68 | 2021-2025 | Rexulti, Vyepti |
| Genzyme Corporation | $227.35 | 2021-2025 | |
| Livanova USA, INC. | $222.20 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $213.36 | 2023-2025 | Hyqvia, Gammagard |
| Axsome Therapeutics, INC. | $186.24 | 2022-2025 | Sunosi |
| Amneal Pharmaceuticals LLC | $173.54 | 2022-2025 | Rytary, Brekiya, Lyvispah |
| Ucb, INC. | $169.38 | 2022-2024 | Briviact, Nayzilam |
| Argenx US, INC. | $155.42 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Tersera Therapeutics LLC | $123.17 | 2021-2023 | Quzyttir |
| Astrazeneca Pharmaceuticals Lp | $111.74 | 2021-2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $95.15 | 2024-2025 | |
| Kyowa Kirin, INC. | $94.52 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $85.74 | 2023-2024 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $71.63 | 2022-2024 | Nuplazid |
| Corium, LLC | $70.57 | 2022-2023 | Adlarity |
| Mallinckrodt Hospital Products INC. | $69.46 | 2022-2025 | Acthar |
| Allergan, INC. | $62.00 | 2021-2022 | |
| Genentech USA, INC. | $60.94 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $48.38 | 2025 | Motpoly Xr |
| Tonix Medicines, INC. | $43.96 | 2025 | Zembrace Symtouch |
| Supernus Pharmaceuticals, INC. | $42.32 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $41.82 | 2021-2022 | |
| Csl Behring | $41.24 | 2022-2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $34.40 | 2025 | Ponvory |
| Mdd US Operations, LLC | $33.24 | 2022-2023 | Apokyn |
| Alvogen INC | $31.81 | 2021 | |
| Merz Pharmaceuticals, LLC | $30.53 | 2021 | |
| Grt US Holding, INC. | $29.21 | 2022 | |
| Medtronic, INC. | $28.63 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $28.53 | 2022 | |
| Abbott Laboratories | $25.20 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.25 | 2025 | |
| Almatica Pharma LLC | $20.87 | 2025 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $19.50 | 2021 | |
| Impel Pharmaceuticals LLC | $16.67 | 2024 | Trudhesa |
| Impel Pharmaceuticals INC. | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Darnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.